['alzheimer disease', 'agitation', 'weight loss', 'pain', 'oxidative stress']
['nabilone', 'placebo']

        Inclusion Criteria:

          -  Males or females ≥55 years of age

          -  Diagnostic and Statistical Manual (DSM) -V criteria for Major Neurocognitive Disorder
             due to AD. Patients with both Major Neurocognitive Disorder due to AD and Major
             Vascular Neurocognitive Disorder (i.e., mixed AD and cerebrovascular disease) will
             also be included.

          -  Currently in moderate-to-severe stage of dementia (Mini-Mental Status Examination
             (MMSE) ≤24)

          -  Presence of clinically significant agitation (Neuropsychiatric Inventory (NPI)
             agitation subscale ≥3)

          -  If treated with cognitive-enhancing medications (cholinesterase inhibitors and/or
             memantine), dosage must be stable for at least 3 months. If the ChEI and/or memantine
             has been discontinued, they may enroll after 1 month.

        Exclusion Criteria:

          -  Change in psychotropic medications less than 1 month prior to study randomization
             (e.g., concomitant antidepressants)

          -  Contraindications to nabilone (history of hypersensitivity to any cannabinoid)

          -  Current or past significant cardiovascular disease (e.g. uncontrolled hypertension,
             ischemic heart disease, arrhythmia and severe heart failure)

          -  Presence or history of other psychiatric disorders or neurological conditions (e.g.
             psychotic disorders, schizophrenia, stroke, epilepsy), previous or current abuse
             of/dependence on marijuana
      